Health

Opinion: My oncologist recommended active surveillance for prostate cancer. Life insurers called it ‘untreated cancer’

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 07/10/2026, 21:21:27 UTC.

Briefings

An individual experienced denial of life insurance due to a minimal prostate cancer diagnosis from three years prior. Eight insurers rejected the application citing 'untreated cancer,' despite the condition being described as tiny and occurring after a heart attack. The policy expired in 2013, and the denial occurred around 2016. The case highlights a conflict between medical advice for active surveillance and insurance underwriting criteria.

Key points

• Eight life insurance companies denied coverage for a policyholder due to a diagnosis of prostate cancer diagnosed three years before the policy expiration.
• The denied cancer was described as 'tiny' and occurred after a heart attack, leading insurers to classify it as 'untreated cancer' rather than a manageable condition.

Context

This incident illustrates a real-world conflict between medical recommendations for active surveillance and insurance underwriting practices, where minor prostate cancer was deemed 'untreated' despite the patient's history of a heart attack.

Limitations

Evidence is limited to a single anecdotal case involving eight insurers; specific denial dates are not provided, and the source does not offer statistical prevalence or broader industry data.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 24/10/2026, 12:16:48 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiec2y3m4ikkcxnlzeetpcdazyghdqfzvxv4shu6tpmt4evuvqxk4a